Johnson & Johnson (NYSE:JNJ – Free Report) had its price target upped by Guggenheim from $244.00 to $266.00 in a research note published on Monday, Marketbeat.com reports. They currently have a buy rating on the stock.
Several other research analysts have also weighed in on JNJ. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Citigroup upped their price target on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. Freedom Capital lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 16th. Raymond James Financial upped their price target on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $252.48.
Get Our Latest Report on Johnson & Johnson
Johnson & Johnson Stock Down 1.6%
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.75%. Johnson & Johnson’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a $1.34 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.12%.
Insider Transactions at Johnson & Johnson
In related news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by company insiders.
Institutional Trading of Johnson & Johnson
Institutional investors have recently bought and sold shares of the business. Blueline Advisors LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at about $25,000. Cresta Advisors Ltd. bought a new stake in Johnson & Johnson in the 4th quarter valued at about $26,000. Abich Financial Wealth Management LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at about $26,000. DecisionPoint Financial LLC boosted its holdings in Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the period. Finally, Bay Harbor Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after acquiring an additional 49 shares during the period. Institutional investors own 69.55% of the company’s stock.
Key Stories Impacting Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Q1 beat-and-raise — J&J reported stronger-than-expected Q1 revenue and EPS, raised full‑year targets and highlighted resilience in Innovative Medicines and MedTech, which supports earnings momentum and the company’s dividend policy. Johnson & Johnson Stock (JNJ) Opinions on Q1 Earnings Release
- Positive Sentiment: Analyst upgrades — Guggenheim raised its price target to $266 and kept a Buy rating, citing upside from Icotyde and model updates after Q1; other brokers have nudged targets higher as well, which supports upside expectations. Guggenheim Adjusts Price Target on Johnson & Johnson to $266 from $244; Maintains Buy Rating
- Positive Sentiment: Income investor appeal — J&J was named among high‑dividend picks (Ray Dalio list) and is being highlighted in dividend-income roundups, reinforcing its attractiveness to yield-focused investors after the recent dividend increase. Johnson & Johnson (JNJ) – One of the 12 High Dividend Stocks Picked by Billionaire Ray Dalio
- Neutral Sentiment: MedTech clinical update — new Tecnis PureSee intraocular lens data were presented, adding credibility to MedTech growth but representing longer‑term value rather than an immediate earnings shock. Johnson & Johnson MedTech Data Sparks Fresh Look At JNJ Valuation
- Neutral Sentiment: Dividend‑income coverage — J&J appears on curated lists of dividend giants, which tends to stabilize long-term demand but may not move the stock immediately. Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter
- Negative Sentiment: Insider and institutional selling — QuiverQuant data show heavy insider sales recently and large institutional position changes (some big reductions), which can pressure short‑term sentiment and amplify profit‑taking after the post‑earnings rally. Johnson & Johnson Stock (JNJ) Opinions on Q1 Earnings Release
Johnson & Johnson Company Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
